Edition:
United States

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

132.25EUR
5:11am EST
Change (% chg)

€0.25 (+0.19%)
Prev Close
€132.00
Open
€132.00
Day's High
€132.70
Day's Low
€131.55
Volume
16,694
Avg. Vol
31,674
52-wk High
€143.20
52-wk Low
€97.17

BIOX.PA

Chart for BIOX.PA

About

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial... (more)

Overall

Beta: 0.31
Market Cap(Mil.): €5,207.89
Shares Outstanding(Mil.): 39.45
Dividend: 1.00
Yield (%): 0.76

Financials

  BIOX.PA Industry Sector
P/E (TTM): 38.15 31.51 30.37
EPS (TTM): 3.46 -- --
ROI: 6.63 13.47 15.17
ROE: 9.31 17.12 16.51

BRIEF-Biomerieux launches system for extraction of DNA and RNA

* Launches EMAG, a new generation automated system for extraction of DNA and RNA

Nov 10 2016

BRIEF-Biomerieux 9 months sales up at 1.51 billion euros

* 9 months sales of 1.51 billion euros versus 1.41 billion euros ($1.55 billion) a year ago

Oct 20 2016

BRIEF-Biomerieux' Filmarray Respiratory Panel EZ is CLIA waived by the FDA

* Filmarray Respiratory Panel EZ (RP EZ) is clia waived by the FDA

Oct 11 2016

BRIEF-Biomerieux introduces Evisight Compact

* Biomerieux introduces Evisight Compact, a new automated diagnostic solution for microbial detection in pharmaceutical production Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Oct 06 2016

BRIEF-Biomerieux 2016 guidance revised to top of range

* H1 net income of consolidated companies 86 million euros ($95.9 million) versus 59 million euros a year ago

Aug 31 2016

BRIEF-Biomerieux H1 sales up 10.9 pct, at constant exchange rates and scope of consolidation

* Strong growth in sales, up 10.9 pct, at constant exchange rates and scope of consolidation in first half of 2016

Jul 18 2016

BRIEF-Biomerieux reports Q2 growth in sales of 10.9 pct

* Q2 strong growth in sales, up 10.9 pct, at constant exchange rates and scope of consolidation in first half of 2016

Jul 18 2016

BRIEF-Biomerieux gets FDA clearance for VIDAS B.R.A.H.M.S PCT test

* Biomerieux receives FDA clearance for expanded use of VIDAS B.R.A.H.M.S PCT test for managing sepsis patients with elevated risk of mortality Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 01 2016

Earnings vs. Estimates